Human monoclonal antibodies targeting infectious pathogens
Document text
Principal Investigator: Joshua Hoong Yu Tan Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES Fiscal Year: 2020 Award: $875,573 Funding agency: National Institute of Allergy and Infectious Diseases The overarching goal of this project is to study the immune response to pathogens at the monoclonal level to increase our understanding of basic biology and develop new tools to combat disease. We are currently focusing our efforts on human monoclonal antibodies against two pathogens, Plasmodium falciparum and SARS-CoV-2. These projects have started recently, so most of our findings are still preliminary at this stage. For SARS-CoV-2, we have screened plasma from >100 acutely infected and convalescent COVID-19 individuals for neutralization of authentic SARS-CoV-2. The top neutralizers were selected for antibody isolation and we have isolated a panel of monoclonals against the SARS-CoV-2 spike protein. Characterization of these antibodies is currently underway, and our hope is to identify antibodies that can potently neutralize the virus and delineate specific epitopes that may be suitable vaccine candidates. For P. falciparum, we are in the process of setting up high-throughput assays to screen for antibodies against various stages of the life cycle, including sporozoites, blood stages and sexual stages. Terms: <2019 novel coronavirus><2019-nCoV><Acute><Antibodies><Antibody Response><Antigenic Determinants><Antigens><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Binding Determinants><Biology><Blood><Blood Plasma><Blood Reticuloendothelial System><COVID-19><COVID-19 epidemic><COVID-19 pandemic><COVID19><COVID19 epidemic><COVID19 pandemic><Chromosomes><Clinical Treatment Moab><Communicable Diseases><Disease><Disorder><Engineering><Epitopes><Genes><Germinal Center><Goals><High Throughput Assay><Hu-mABs><Human><Immune response><Immunological response><Individual><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Learning><Life Cycle><Life Cycle Stages><Modern Man><Monoclonal Antibodies><P falciparum><P. falciparum><P.falciparum><Plasma><Plasma Serum><Plasmodium><Plasmodium falciparum><Process><Prophylactic treatment><Prophylaxis><Proteins><R-Series Research Projects><R01 Mechanism><R01 Program><Reaction><Research Grants><Research Project Grants><Research Projects><Resolution><Reticuloendothelial System, Serum, Plasma><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Severe acute respiratory syndrome coronavirus 2><Site><Somatic Mutation><Sporozoites><Structure of germinal center of lymph node><Surface><Technology><Vaccine Design><Vaccines><Virus><Wuhan coronavirus><base><combat><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 epidemic><coronavirus disease 2019 pandemic><cost><fighting><high throughput screening><host response><humAbs><human mAbs><human monoclonal antibodies><human monoclonals><immunogen><immunoresponse><improved><life course><mAbs><pathogen><prevent><preventing><response><tool><vaccine candidate>